Kite Pharma announces updated Zuma-3 data from KTE-X19 Phase 1/2 study

Kite, a Gilead Company, announced updated results from ZUMA-3, a single-arm Phase 1/2 study evaluating KTE-X19, an investigational CD19 chimeric antigen receptor T cell therapy, in adult patients with relapsed or refractory acute lymphoblastic leukemia. With a median follow-up of 15.1 months following a single infusion of KTE-X19, 69 percent of evaluable patients achieved complete tumor remission, defined as complete remission or CR with incomplete hematological recovery. The rate of undetectable minimal residual disease in patients who achieved complete tumor remission was 100%. Adverse events were consistent with the known toxicities of CD19 CAR T treatment, including Grade 3 or higher cytokine release syndrome and neurologic events in 23% and 39% of patients, respectively. The majority of these adverse events were resolved, with the exception of two patients who had ongoing neurological events at the time of death from other causes. Two patients died from adverse events deemed by the treating investigator to be related to KTE-X19.
https://thefly.com/landingPageNews.php?id=2831635